検索結果

Product Development Policy | Research & Development | SENJU Pharmaceutica

etina, cause bleeding and edema. In recent drug therapies, intravitreal injection of antibody drugs targeting the vascular endothelial growth factor (VEGF) protein, which increases angiogenesis and le...

announce today that it has been applied for manufacturing and marketing approval in Japan. DED, the target disease of SJP-0132, is defined as “A multifactorial disease characterized by an unstable tea...

c atrophy secondary to age-related macular degeneration and the complement pathway as a therapeutic target. Retina. 2017;37(5):819-835. 2 Cheung, C.M.G., Chen, Y., Holz, F.G. et al. Geographic atrophy...

administration trial demonstrated positive results confirming the safety of clinical use. DED, the target disease of SJP-0132, is defined as “A multifactorial disease characterized by an unstable tea...

iod required for regulatory approval, resulting in early approval and launch. CRAO, the therapeutic target of SJP-0008, occurs when central retinal artery occlusion leads to irreversible impairment of...